Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 28;10:5428. doi: 10.1038/s41467-019-13315-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — Efficacy of ceritinib and AZD1208 in driven patient-derived NB xenografts. a Tumor volume over time in COG-N-426x PDX mice administered daily with vehicle (0.5% hydroxypropyl methylcellulose, 0.5% Tween-80), ceritinib (30 mg/kg), AZD1208 (15 mg/kg), or ceritinib and AZD1208 (combo). Data points represent means (n = 4) ± s.e.m. and are shown until death of the first animal within each treatment group. *p < 0.05; **p < 0.005 (Mann–Whitney test). b Kaplan–Meier event-free survival according to each treatment group for tumor-bearing COG-N-426x mice, where survival is defined as the time taken for tumors to reach 15 mm diameter. *p < 0.01 (Log-rank test). c COG-N-426x mouse body weight at the experiment end-point relative to baseline per treatment group. Data points represent means (n = 4) ± s.d. *p > 0.05 (unpaired Student’s t-test). d Tumor volume over time for COG-N-453x PDX mice administered daily with vehicle (0.5% hydroxypropyl methylcellulose, 0.5% Tween-80), ceritinib (30 mg/kg), AZD1208 (15 mg/kg), or ceritinib and AZD1208 (combo). Data points represent means (n = 4) + s.e.m. and are shown until death of the first animal within each treatment group. **p < 0.005 (Mann–Whitney test). e Kaplan–Meier survival curve per treatment group for tumor-bearing COG-N-453x mice, where survival is defined as the time taken for tumors to reach 15 mm diameter. The study was terminated on day 37, thus censoring one mouse (**). *p < 0.01 (Log-rank test). f PIM1 mRNA levels at the experimental end-point for COG-N-426x tumor-bearing mice per treatment group. Data points represent means (n = 4) ± s.d. of triplicate experiments, *p < 0.05; **p < 0.01 (unpaired Student’s t-test). Source data for this figure are provided as a Source Data file.